UNSPSC 51294511: Panuramine

This classification denotes an antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1UWS3T8EAB. European Medicines Agency schedules Panuramine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09609MIG. Panuramine generally arises in the molecular formula C24H25N3O2.

UNSPSC 51294511 Panuramine is a Commodity code covering pharmaceutical products — specifically naloxone, drug deactivation systems, and generic multi-source pharmaceuticals and over-the-counter products — that state and local health agencies, county health departments, and cooperative purchasing alliances procure for community health initiatives, pharmacy benefit programs, and emergency medical response. State and local buyers under this code include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The work involves both direct product procurement through competitive bidding and strategic market intelligence gathering to inform pharmacy benefit program design and manufacturer relationships, with vendors required to meet federal compliance standards including cGMP certification, Drug Supply Chain Security Act (DSCSA) adherence, E-Verify requirements, and specific insurance coverage minimums.

Recent activity spans Florida, Texas, and Minnesota-based cooperative purchasing. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, with a response deadline of July 26, 2023, under a fixed-fee contract with a two-year initial term and one-year renewal option. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities regarding direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels, signaling the state's intent to develop a formal RFP following this exploratory phase. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026, effective July 1, 2026, through authorized wholesalers AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC, with evaluation weighted 75 percent on price competitiveness and the remainder on fixed pricing, administrative compliance, EDI capability, and administrative fee acceptance.